Cargando…

Retargeting Strategies for Oncolytic Herpes Simplex Viruses

Most of the oncolytic herpes simplex viruses (HSVs) exhibit a high safety profile achieved through attenuation. They carry defects in virulence proteins that antagonize host cell response to the virus, including innate response, apoptosis, authophagy, and depend on tumor cell proliferation. They gro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Campadelli-Fiume, Gabriella, Petrovic, Biljana, Leoni, Valerio, Gianni, Tatiana, Avitabile, Elisa, Casiraghi, Costanza, Gatta, Valentina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810253/ https://www.ncbi.nlm.nih.gov/pubmed/26927159 http://dx.doi.org/10.3390/v8030063

Ejemplares similares

A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells
por: Leoni, Valerio, et al.
Publicado: (2017)

Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors
por: Leoni, Valerio, et al.
Publicado: (2018)

Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells
por: Petrovic, Biljana, et al.
Publicado: (2018)

HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses
por: Menotti, Laura, et al.
Publicado: (2018)

Efficacy of Systemically Administered Retargeted Oncolytic Herpes Simplex Viruses—Clearance and Biodistribution in Naïve and HSV-Preimmune Mice
por: Vannini, Andrea, et al.
Publicado: (2023)

Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins
por: Petrovic, Biljana, et al.
Publicado: (2017)

A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors
por: Leoni, Valerio, et al.
Publicado: (2018)

Immunotherapeutic Efficacy of Retargeted oHSVs Designed for Propagation in an Ad Hoc Cell Line
por: Vannini, Andrea, et al.
Publicado: (2021)

Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers
por: Vannini, Andrea, et al.
Publicado: (2023)

Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis
por: Sasso, Emanuele, et al.
Publicado: (2020)

Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma
por: Appolloni, Irene, et al.
Publicado: (2021)

Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases
por: Leoni, Valerio, et al.
Publicado: (2015)

The Engineering of a Novel Ligand in gH Confers to HSV an Expanded Tropism Independent of gD Activation by Its Receptors
por: Gatta, Valentina, et al.
Publicado: (2015)

Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV
por: Gianni, Tatiana, et al.
Publicado: (2021)

Preclinical Therapy of Disseminated HER-2(+) Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
por: Nanni, Patrizia, et al.
Publicado: (2013)

Potent anti-tumor effects of receptor-retargeted syncytial oncolytic herpes simplex virus
por: Suzuki, Takuma, et al.
Publicado: (2021)

Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment
por: De Lucia, Maria, et al.
Publicado: (2020)

Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy
por: Menotti, Laura, et al.
Publicado: (2020)

Towards a Precision Medicine Approach and In Situ Vaccination against Prostate Cancer by PSMA-Retargeted oHSV
por: Vannini, Andrea, et al.
Publicado: (2021)

Generation of a Retargeted Oncolytic Herpes Virus Encoding Adenosine Deaminase for Tumor Adenosine Clearance
por: Gentile, Chiara, et al.
Publicado: (2021)

Generation of an Oncolytic Herpes Simplex Viral Vector Completely Retargeted to the GDNF Receptor GFRα1 for Specific Infection of Breast Cancer Cells
por: Hall, Bonnie L., et al.
Publicado: (2020)

Retargeting of Viruses to Generate Oncolytic Agents
por: Verheije, M. H., et al.
Publicado: (2012)

Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018)

The Epithelial αvβ3-Integrin Boosts the MYD88-Dependent TLR2 Signaling in Response to Viral and Bacterial Components
por: Gianni, Tatiana, et al.
Publicado: (2014)

αvβ3-integrin regulates PD-L1 expression and is involved in cancer immune evasion
por: Vannini, Andrea, et al.
Publicado: (2019)

Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
por: Aldrak, Norah, et al.
Publicado: (2021)

Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy
por: Ning, Jianfang, et al.
Publicado: (2014)

Presage of oncolytic virotherapy for oral cancer with herpes simplex virus
por: Yura, Yoshiaki
Publicado: (2017)

The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment
por: Nguyen, Hong-My, et al.
Publicado: (2021)

Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors
por: Hong, Bangxing, et al.
Publicado: (2022)

Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of Herpes Simplex Oncolytic Virus
por: Froechlich, Guendalina, et al.
Publicado: (2020)

Treatment of breast cancer stem cells with oncolytic herpes simplex virus
por: Li, J, et al.
Publicado: (2012)

Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Neuroblastoma
por: Gillory, Lauren A., et al.
Publicado: (2013)

Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy
por: Yin, Jie, et al.
Publicado: (2017)

Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo
por: Ghose, Jayeeta, et al.
Publicado: (2021)

Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers
por: Scanlan, Hayle, et al.
Publicado: (2022)

Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma
por: Hu, Mingming, et al.
Publicado: (2023)

Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus
por: Hill, Claudia, et al.
Publicado: (2021)

Stability and anti-tumor effect of oncolytic herpes simplex virus type 2
por: Wang, Yang, et al.
Publicado: (2018)

Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA
por: Boscheinen, Jan B., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_02csqolji65f5m27429f0rtusl